| Bioactivity | Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2]. |
| CAS | 155648-60-5 |
| Formula | C9H14N2O8P2 |
| Molar Mass | 340.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61. [2]. Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63. |
Minodronic acid hydrate
CAS: 155648-60-5 F: C9H14N2O8P2 W: 340.16
Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferatio
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.